» Articles » PMID: 22456181

Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis

Abstract

Rationale: Multiple sclerosis (MS) and its mouse model, experimental autoimmune encephalomyelitis (EAE), are inflammatory disorders of the central nervous system (CNS). The function of platelets in inflammatory and autoimmune pathologies is thus far poorly defined.

Objective: We addressed the role of platelets in mediating CNS inflammation in EAE.

Methods And Results: We found that platelets were present in human MS lesions as well as in the CNS of mice subjected to EAE but not in the CNS from control nondiseased mice. Platelet depletion at the effector-inflammatory phase of EAE in mice resulted in significantly ameliorated disease development and progression. EAE suppression on platelet depletion was associated with reduced recruitment of leukocytes to the inflamed CNS, as assessed by intravital microscopy, and with a blunted inflammatory response. The platelet-specific receptor glycoprotein Ibα (GPIbα) promotes both platelet adhesion and inflammatory actions of platelets and targeting of GPIbα attenuated EAE in mice. Moreover, targeting another platelet adhesion receptor, glycoprotein IIb/IIIa (GPIIb/IIIa), also reduced EAE severity in mice.

Conclusions: Platelets contribute to the pathogenesis of EAE by promoting CNS inflammation. Targeting platelets may therefore represent an important new therapeutic approach for MS treatment.

Citing Articles

A New Perspective on Mechanisms of Neurodegeneration in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: the Early and Critical Role of Platelets in Neuro/Axonal Loss.

Orian J J Neuroimmune Pharmacol. 2025; 20(1):14.

PMID: 39904925 PMC: 11794395. DOI: 10.1007/s11481-025-10182-w.


Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.

Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q Biomark Res. 2024; 12(1):164.

PMID: 39736771 PMC: 11686937. DOI: 10.1186/s40364-024-00700-y.


Circulating platelets modulate oligodendrocyte progenitor cell differentiation during remyelination.

Philp A, Reyes C, Mansilla J, Sharma A, Zhao C, Valenzuela-Krugmann C Elife. 2024; 12.

PMID: 39163103 PMC: 11335344. DOI: 10.7554/eLife.91757.


Targeting Vascular Impairment, Neuroinflammation, and Oxidative Stress Dynamics with Whole-Body Cryotherapy in Multiple Sclerosis Treatment.

Dziedzic A, Maciak K, Miller E, Starosta M, Saluk J Int J Mol Sci. 2024; 25(7).

PMID: 38612668 PMC: 11011409. DOI: 10.3390/ijms25073858.


Whole-Body Cryostimulation in Multiple Sclerosis: A Scoping Review.

Alito A, Fontana J, Franzini Tibaldeo E, Verme F, Pitera P, Miller E J Clin Med. 2024; 13(7).

PMID: 38610768 PMC: 11012586. DOI: 10.3390/jcm13072003.


References
1.
Hu X, Wohler J, Dugger K, Barnum S . beta2-integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol. 2009; 87(3):397-403. PMC: 3212424. DOI: 10.1189/jlb.1009654. View

2.
Baxter A . The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007; 7(11):904-12. DOI: 10.1038/nri2190. View

3.
Sheremata W, Jy W, Horstman L, Ahn Y, Alexander J, Minagar A . Evidence of platelet activation in multiple sclerosis. J Neuroinflammation. 2008; 5:27. PMC: 2474601. DOI: 10.1186/1742-2094-5-27. View

4.
Han M, Hwang S, Roy D, Lundgren D, Price J, Ousman S . Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008; 451(7182):1076-81. DOI: 10.1038/nature06559. View

5.
Weiner H, Selkoe D . Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002; 420(6917):879-84. DOI: 10.1038/nature01325. View